A meeting was held in the Cabinet of Ministers with the participation of representatives of the Association of the Pharmaceutical Industry of Kyrgyzstan. The press service of the Cabinet of Ministers reported.
According to it, the Deputy Chairman of the Cabinet of Ministers Bakyt Torobaev noted that the main goal of state support is the development of the pharmaceutical industry of Kyrgyzstan and the adoption of timely and effective measures necessary to protect the domestic production of quality medicines. He called on the Association to more actively submit initiative proposals to the Cabinet of Ministers and relevant departments to create favorable conditions for the development of the pharmaceutical industry.
In turn, representatives of the Association voiced problems and issues related to the postponement of the mandatory compliance with the requirements of good manufacturing practice of the Eurasian Economic Union (EAEU GMP) until 2030. They asked for support from the Cabinet of Ministers in the implementation of planned production mechanisms for guaranteed sales of manufactured products, the allocation of subsidies for the implementation of EAEU GMP, and also made a proposal to introduce VAT on imports on certain types of manufactured medicines.
The Cabinet of Ministers noted that the main reason for the need to postpone the introduction of the EAEU GMP is the insufficiency of financial resources for technological re-equipment of domestic manufacturers and personnel training until December 31, 2025.
As a result of the meeting, instructions were given to the Ministry of Health, including developing a roadmap for the development of the domestic pharmaceutical industry, including measures such as the introduction of VAT on imports of domestic products produced in sufficient volumes, the development of mechanisms to ensure the availability of domestic medicines in the retail pharmacy network, and an increase in the production of medical products with increasing the volume from 3 percent to 20 percent, a program for financing and protecting the pharmaceutical industry in preferential treatment.
